Process development demonstrates scalable synthesis of a BTK degrader, indicating effective methods for large-scale production.
We present the process development of 1, a heterobifunctional Bruton’s Tyrosine Kinase (BTK) degrader. Optimization and reorganization of the discovery synthesis resulted in a scalable process suitable for preparation of API for the GLP-Tox (600 g) and planned FIH studies (5.7 kg). The FIH process achieved an average yield of 86% over the final four stages. Selective optimization of reaction conditions, modeling and high-throughput experimentation were applied strategically to address scale up challenges posed by this novel class of API.
No takes yet. Share an insight, caveat, or question.
Haibach et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: